• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy.慢性荨麻疹的真实世界疾病负担与疫苗犹豫
Allergy Asthma Immunol Res. 2023 Jan;15(1):1-3. doi: 10.4168/aair.2023.15.1.1.
2
The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.慢性自发性荨麻疹负担沉重：ASSURE-CSU 的真实世界证据。
Allergy. 2017 Dec;72(12):2005-2016. doi: 10.1111/all.13209. Epub 2017 Jul 10.
3
Humanistic Burden of Refractory and Nonrefractory Chronic Idiopathic Urticaria: A Real-world Study in the United States.难治性和非难治性慢性特发性荨麻疹的人文负担：美国真实世界研究。
Clin Ther. 2019 Feb;41(2):205-220. doi: 10.1016/j.clinthera.2018.12.004. Epub 2018 Dec 31.
4
Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use.探索美国难治性和非难治性慢性特发性荨麻疹的真实世界特征：临床负担和医疗资源利用。
Curr Med Res Opin. 2019 Aug;35(8):1387-1395. doi: 10.1080/03007995.2019.1586222. Epub 2019 Mar 28.
5
Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.意大利慢性荨麻疹患者的社会经济负担及资源利用情况：AWARE研究的2年数据
World Allergy Organ J. 2020 Dec 8;13(12):100470. doi: 10.1016/j.waojou.2020.100470. eCollection 2020 Dec.
6
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria.ASSURE-CSU：一项关于有症状慢性自发性荨麻疹患者疾病负担的真实世界研究。
Clin Transl Allergy. 2015 Aug 17;5:29. doi: 10.1186/s13601-015-0072-9. eCollection 2015.
7
[Influenza vaccine hesitancy among health workers, Bahia State, Brazil].[巴西巴伊亚州医护人员对流感疫苗的犹豫态度]
Cad Saude Publica. 2022 Jan 31;38(1):e00098521. doi: 10.1590/0102-311X00098521. eCollection 2022.
8
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.从皮肤科角度抑制 COVID-19 疫苗犹豫：疫苗不良事件报告系统 (VAERS) 数据库中皮肤反应的分析。
Am J Clin Dermatol. 2022 Sep;23(5):729-737. doi: 10.1007/s40257-022-00715-x. Epub 2022 Aug 5.
9
Parental childhood vaccine hesitancy and predicting uptake of vaccinations: a systematic review.家长对儿童疫苗的犹豫态度及其对接种疫苗的预测：系统综述。
Prim Health Care Res Dev. 2022 Nov 4;23:e68. doi: 10.1017/S1463423622000512.
10
Vaccine Hesitancy: Contemporary Issues and Historical Background.疫苗犹豫：当代问题与历史背景
Vaccines (Basel). 2022 Sep 22;10(10):1595. doi: 10.3390/vaccines10101595.

引用本文的文献

1
Exploring the content validity of the EQ-5D-5L and four bolt-ons (skin irritation, self-confidence, sleep, social relationships) in atopic dermatitis and chronic urticaria.探索EQ-5D-5L及四个附加项目（皮肤刺激、自信心、睡眠、社会关系）在特应性皮炎和慢性荨麻疹中的内容效度。
Qual Life Res. 2025 Apr;34(4):991-1002. doi: 10.1007/s11136-024-03875-x. Epub 2024 Dec 14.

本文引用的文献

1
Chronic Spontaneous Urticaria in Hong Kong: Clinical Characteristics, Real-World Practice and Implications for COVID-19 Vaccination.香港慢性自发性荨麻疹：临床特征、实际应用及对新冠疫苗接种的影响
Allergy Asthma Immunol Res. 2023 Jan;15(1):32-42. doi: 10.4168/aair.2023.15.1.32.
2
Urticaria relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single-center experience.抗组胺药联合奥马珠单抗治疗慢性自发性荨麻疹患者接种 mRNA COVID-19 疫苗后荨麻疹复发：单中心经验。
Dermatol Ther. 2022 Nov;35(11):e15838. doi: 10.1111/dth.15838. Epub 2022 Sep 27.
3
The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea.韩国一项真实世界研究：慢性自发性荨麻疹症状患者的负担。
Korean J Intern Med. 2022 Sep;37(5):1050-1060. doi: 10.3904/kjim.2022.078. Epub 2022 Sep 1.
4
Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study.新冠病毒疫苗接种对慢性自发性和诱导性荨麻疹（CSU/CIU）患者的影响：一项单中心研究。
J Clin Med. 2022 Mar 25;11(7):1822. doi: 10.3390/jcm11071822.
5
Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy.对 COVID-19 疫苗过敏的理解迅速取得进展：令人乐观而非犹豫。
J Allergy Clin Immunol. 2022 Jul;150(1):12-16. doi: 10.1016/j.jaci.2022.03.023. Epub 2022 Apr 7.
6
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.过敏与 COVID-19 疫苗：ENDA/EAACI 立场文件。
Allergy. 2022 Aug;77(8):2292-2312. doi: 10.1111/all.15241. Epub 2022 Mar 5.
7
Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.接种 BNT162b2 mRNA（辉瑞-生物科技）疫苗后出现慢性自发性荨麻疹，以预防 SARS-CoV-2。
Allergy Asthma Proc. 2022 Jan 1;43(1):30-36. doi: 10.2500/aap.2022.43.210111.
8
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.国际 EAACI/GA²LEN/EuroGuiDerm/APAAACI 荨麻疹定义、分类、诊断和管理指南。
Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090. Epub 2021 Oct 20.
9
Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.高过敏风险成年人接种辉瑞-BioNTech COVID-19 疫苗后的过敏反应发生率。
JAMA Netw Open. 2021 Aug 2;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255.
10
Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.预先警告即预先武装：慢性自发性荨麻疹对有效接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗及全球公共卫生构成潜在风险。
Br J Dermatol. 2021 Oct;185(4):838-839. doi: 10.1111/bjd.20495. Epub 2021 Jul 22.

Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy.

作者信息

Ban Ga-Young, Ye Young-Min

机构信息

Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.

出版信息

Allergy Asthma Immunol Res. 2023 Jan;15(1):1-3. doi: 10.4168/aair.2023.15.1.1.

DOI:10.4168/aair.2023.15.1.1
PMID:36693352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9880297/
Abstract
摘要